Clinical Trial Update: Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma [NA]

View source ↗

Summary

A multicenter Phase 2 trial evaluating subcutaneous isatuximab in combination with bortezomib, lenalidomide, and dexamethasone for newly diagnosed transplant-in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Revlimid (lenalidomide)
• SARCLISA (isatuximab)
• Velcade (bortezomib)

Snippet

Sponsor: Poitiers University Hospital | Conditions: Multiple Myeloma, Myeloma Multiple | NA | Status: ACTIVE_NOT_RECRUITING